Elsevier

Life Sciences

Volume 62, Issue 1, 28 November 1997, Pages 77-91
Life Sciences

Alendronate induces gastric injury and delays ulcer healing in rodents

https://doi.org/10.1016/S0024-3205(97)01040-0Get rights and content

Abstract

Gastric ulceration associated with the use of NSAIDs is most frequently observed in elderly women, the same sector of society most likely to be receiving therapy for osteoporosis. As some anti-osteoporosis medications have been suggested to irritate the upper gastrointestinal mucosa, we evaluated the ability of one such drug, alendronate, to damage the gastric mucosa and to influence the severity and healing of gastric ulcers in rodents. The effects of alendronate on indomethacin-induced antral ulceration was evaluated in the rabbit, while effects on ulcer healing and on the formation of gastric erosions was evaluated in the rat. Effects of alendronate on gastric acid secretion, blood flow and prostaglandin synthesis were also evaluated. Alendronate caused erosions in the rabbit stomach, but not antral ulceration. However, at the highest doses tested (80 mg) alendronate increased the incidence and size of indomethacin-induced antral ulcers. Alendronate also enhanced indomethacin-induced gastric damage in the rat, and delayed gastric ulcer healing. These effects of alendronate were not attributable to changes in gastric acid secretion, blood flow, prostaglandin synthesis or the pharmacokinetics of indomethacin. The damaging effects of alendronate on the stomach were due to topical irritant effects and could be observed at concentrations as low as 4 mg/ml within 30 min of oral administration or topical superfusion. These results support preliminary clinical evidence that alendronate can damage the gastric mucosa. While gastric injury may be a rare occurrence in patients taking this drug, concomitant use of alendronate and NSAIDs may increase the incidence or severity of ulceration.

References (28)

  • R. Pounder

    Gastroenterology

    (1989)
  • S.N. Elliott et al.

    Gastroenterology

    (1995)
  • J.Y. Wang et al.

    Gastroenterology

    (1989)
  • D.M. Mccafferty et al.

    Gastroenterology

    (1995)
  • J.G.P. Ferraz et al.

    Gastroenterology

    (1995)
  • J.L. Wallace et al.

    Gastroenterology

    (1994)
  • L.J. Dusci et al.

    J. Chromatogr.

    (1979)
  • D.M. Black et al.

    The Lancet

    (1996)
  • S. Adami et al.

    Bone

    (1994)
  • J.L. Wallace

    Gastroenterology

    (1997)
  • J.H. Lin et al.

    J. Pharmaceut. Sci.

    (1994)
  • J.L. Wallace et al.

    Gastroenterology

    (1986)
  • N.H. Bell et al.

    Am. J. Med.

    (1994)
  • D.R. Lichtenstein et al.

    Arthritis Rheum.

    (1995)
  • Cited by (83)

    • Reduced food interaction and enhanced gastrointestinal tolerability of a new system based on risedronate complexed with Eudragit E100: Mechanistic approaches from in vitro and in vivo studies

      2016, European Journal of Pharmaceutics and Biopharmaceutics
      Citation Excerpt :

      Again, all differences were statistically significant (p < 0.0001). It is known that gastric damage caused by aminobisphosphonates is a result of their topical irritant effects on the mucosa [29,41,42]. Thus, the reduction in the gastric irritation potential observed with the EuE100-Ris50 treatment could have been related to the reduction in the concentration of free Ris observed in this work.

    • Alendronate-calcium phosphate hybrid films promoted the osteoblast differentiation and inhibited osteoclastogenic activity

      2015, Journal of Industrial and Engineering Chemistry
      Citation Excerpt :

      OB synthesizes extracellular matrix proteins including collagen and non-collagenous proteins and regulates matrix mineralization [15]. OC is a highly specialized multinucleate giant cell differentiated from monocyte/macrophage lineage of bone marrow hematopoietic cells and responsible for bone resorption [16,17]. Interestingly, two factors including macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL) required for OC formation, survival and function, are provided by bone marrow OBs [18].

    • Progress on the preparation of nanocrystalline apatites and surface characterization: Overview of fundamental and applied aspects

      2013, Progress in Crystal Growth and Characterization of Materials
      Citation Excerpt :

      The classic BPs treatment is the systemic way by oral administration or intravenous injection. However, undesirable side-effects like fever [265], ulcers [266,267] or osteonecrosis of the jaw [267,268] are commonly observed by systemic use of BPs. Moreover low bioavailability is commonly observed for oral administration [269].

    • Bioceramics for drug delivery

      2013, Acta Materialia
    • Role of soluble guanylate cyclase activation in the gastroprotective effect of the HO-1/CO pathway against alendronate-induced gastric damage in rats

      2013, European Journal of Pharmacology
      Citation Excerpt :

      Some works have demonstrated that CO activates sGC (Ryter and Otterbein, 2004; Morita et al., 1995) and ODQ treatment completely abolished the protective effect of HO-1 against non-steroidal anti-inflammatory drugs and ethanol-induced gastric damage (Gomes et al., 2010; Freitas et al., 2006). Several studies have suggested that bisphosphonates have a direct irritant effect on the gastric mucosa (Graham and Malaty, 1999; Blank et al., 1997; Elliott et al., 1998), i.e., to decrease the hydrophobic barrier (Lichtenberger et al., 2000). This damaging effect is not due to a decline in the levels of mucosal prostaglandins (Marshall et al., 2000), but through topical irritant action.

    View all citing articles on Scopus
    View full text